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Abstract
A new SARS animal model was established by inoculating SARS coronavirus (SARS-CoV)
into rhesus macaques (Macaca mulatta) through the nasal cavity. Pathological pulmonary
changes were successively detected on days 5–60 after virus inoculation. All eight animals
showed a transient fever 2–3 days after inoculation. Immunological, molecular biological,
and pathological studies support the establishment of this SARS animal model. Firstly,
SARS-CoV-specific IgGs were detected in the sera of macaques from 11 to 60 days after
inoculation. Secondly, SARS-CoV RNA could be detected in pharyngeal swab samples
using nested RT-PCR in all infected animals from 5 days after virus inoculation. Finally,
histopathological changes of interstitial pneumonia were found in the lungs during the
60 days after viral inoculation: these changes were less marked at later time points,
indicating that an active healing process together with resolution of an acute inflammatory
response was taking place in these animals. This animal model should provide insight into the
mechanisms of SARS-CoV-related pulmonary disease and greatly facilitate the development
of vaccines and therapeutics against SARS.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
SARS is a newly emerging and highly communicable
infectious disease of humans that was first detected
in South China in November 2002 and then spread
globally. Much has been learned about this syndrome,
including the epidemiology and transmissibility of
SARS-CoV infections and the clinical manifestations
of disease [1–6]. Resurgence of SARS remains a dis-
tinct possibility in the post-outbreak period [7]. There
is therefore an urgent need to establish a reliable
animal model for understanding the pathogenesis of
SARS-CoV infection and for developing vaccines and
antiviral drugs for the prevention and treatment of
SARS.
Cynomolgus macaques (Macaca fascicularis) [7,8],
ferrets (Mustela furo), and domestic cats (Felis domes-
ticus) are susceptible to infection by SARS-CoV
[9,10]. Replication of SARS-CoV in the respira-
tory tract of mice has also been recently demon-
strated [11]. However, the long-term sequelae of
SARS-CoV infection with respect to progression of
the histopathological changes, the degree of immuno-
logical reaction, and the duration of virus replica-
tion in these animal models are largely unknown.
Given the importance of developing a non-human
primate model for elucidating the pathophysiologi-
cal mechanisms of lung injury and developing new
treatments for SARS, we investigated the susceptibil-
ity of rhesus macaques (Macaca mulatta) to SARS-
CoV infection through nasal cavity inoculation. The
pathological changes in lungs and other organs after
SARS-CoV-inoculation, the replication and excretion
of SARS-CoV in vivo, and the immune response
specific for SARS-CoV in all macaques were stud-
ied at different times after virus infection. In this
paper, we report our findings on the molecular detec-
tion of SARS-CoV replication in vivo, the timing of
seroconversion and development of neutralizing anti-
body response, and the dynamic pathological changes
in the lungs of infected animals over a 60-day
period.
Copyright  2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Materials and methods
Animals
All macaques, aged 1–3 years, were obtained from
the Institute of Medical Biology (Kunming, China),
CAMS and PUMC, and numbered as 1951, 2372,
0227, 1924, 1921, 900, 883, and 2373. Before inocu-
lation with SARS virus, the monkeys were examined
according to the national microbiological and para-
site SPF (specific pathogen-free) standard and were
verified free of anti-SARS antibody. The experiments
were performed in BL-3 level laboratories exclusively
assigned for SCV research at the Institute of Labora-
tory Animal Science of CAMS, with an animal study
protocol approved by the Institutional Animal Welfare
Committee. The macaques were sacrificed according
to the study design described in Table 1. This design
was the result of a preliminary experiment with four
rhesus monkeys sacrificed on the fourth, eighth, 12th,
and 16th day post-infection. This experiment showed
that the lung lesions were much worse in two mon-
keys, ie 4 and 8 days after inoculation, and the inflam-
matory response still persisted on the 16th day post-
inoculation. On the basis of these data and the autopsy
findings of human SARS patients, monkeys prepared
for this experiment were examined on the fifth, tenth,
15th, 20th, 30th, and 60th day post-infection, with the
study design focusing on the behaviour of the acute
inflammatory response after virus infection. In addi-
tion, the possibility of complications such as emphy-
sema, proliferation of fibrous tissue, lung fibrosis, and
pleural adhesion at the later stages (60 days) of infec-
tion were examined.
Virus
SARS-CoV strain PUMC01 was isolated from a
SARS patient in China and cultured with Vero-E6
cells (Genebank accession No AY350 750). The 11th
passage virus was used and its TCID50 (tissue culture
infectious dose 50) was 106 per ml titred on Vero-E6
cells [12]. The virus was not resequenced after the
initial isolation and DNA sequencing.
Virus inoculation
In a preliminary experiment, monkeys were infected
with 103, 105, and 107 TCID. 105 TCID was identified
Table 1. Sacrifice design in SARS-CoV-infected Macaca mulatta
Macaque
identification No Days after sacrifice
2373 5
1924 7
1951 10
883 15
227 20
1921 30
900 60
2372 60
as the optimum dose and was inoculated in a volume
of 1 ml (after ten-fold dilution of 106 per ml stock)
into monkeys 900, 2372, 0227, 883, 2373, 1924, and
1921 by dripping into the nasal cavity. Two millilitres
of 10% (w/v) lung tissue lysate from a clinically
diagnosed SARS patient infected with SARS-CoV
strain PUMC01 was inoculated into monkey 1951
intravenously and via the nasal cavity.
Observations on clinical signs
The animals were subjected to daily measurement
of anal temperature, routine blood assays, and chest
radiography.
Nested RT-PCR for SARS-CoV
The pharyngeal swab samples were collected from
infected monkeys from the first day after inoculation
and were tested for SARS-CoV by nested RT-
PCR. RNAs were isolated with TRIZOL (Invitro-
gen). RT-PCR was performed in 50 µl of reaction
volume with 25 mM MgCl2, outer primer pair (5′-
GCTGCATTGGTTTGT-TATATCGTTATGC-3′) and
(5′-ATACAGAATACAT-AGATTGCTGTTATCC-3′),
inner primer pair (5′-TCACTTGCTTCCGTTGAGGT
AGCCAGCGTGGT-GGTTCATACAA-3′), and (5′-G
GTTTCGGATGTTA-CAGCGTCTCCCGGCAGAAA
GCTGTAAGCT-3′). The amplification parameters
used were sequentially as follows: outer primer pair:
50 ◦C, 30 min for reverse transcription, then 30 s at
94 ◦C, 30 s at 55 ◦C, and 1 min at 72 ◦C for 30 cycles,
followed by a final extension for 10 min at 72 ◦C; inner
primer pair: 10 min at 37 ◦C, 10 min at 94 ◦C; 30 s at
94 ◦C, 30 s at 60 ◦C, and 1 min at 72 ◦C for 32 cycles,
followed by a final extension for 10 min at 72 ◦C. All
PCR products were verified by nucleotide sequencing.
Isolation of SARS-CoV
At 2, 5, and 7 days post-infection, the pharyngeal swab
samples from the infected macaques were inoculated
onto Vero-E6 cells and cultured in DMEM (Gibco,
USA). For virus isolation, at least three to four pas-
sages of the isolates were carried out on Vero-E6 cells.
Both cytopathic effect (CPE) and immunofluorescence
assay (IFA) (incubation with 1 : 10 dilution of SARS
patient serum) were used to determine the infection
status of the animals.
Antibody detection
Just before infection, and on days 5, 9, 13, 17, 20,
and so on after virus inoculation, blood samples were
collected from each animal for SARS-CoV antibody
assay by ELISA (ELISA kit; Huada S20030004, Bei-
jing, China). The plates were coated with cell lysates
from SARS-CoV-infected Vero-E6 cells. All samples
were run in duplicate and simultaneously incubated
at 37 ◦C for 1 h, washing for six times with PBS-
T. Plates were blocked once again for 30 min at
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37 ◦C and washed five times. 100 µl of horseradish
peroxidase (HRP)-conjugated mouse anti-monkey IgG
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA)
was added to the wells and incubated for 1 h at
37 ◦C and then washed six times with PBS-T, devel-
oped with 100 µl of 3,3,5,5-tetramethylbenzidine solu-
tion (Roche-Boehringer-Mannheim, Mannheim, Ger-
many), and stopped with 100 µl of 2 M sulphuric acid.
Plates were read spectrophotometrically at 450 nm in
a microplate reader (Labsystems IEMS, Helsinki, Fin-
land). Samples with OD < 0.16 were considered neg-
ative. This cut-off point was determined using serum
from a normal rhesus monkey that produced no colour
development by immunofluorescence of SARS-CoV-
infected Vero cells as a negative control.
To determine neutralization activity, the macaques’
serum was serially diluted two-fold from 1 : 2 to 1 : 512
and incubated with 102 TCID SARS-CoV for 1 h at
37 ◦C, and then inoculated onto Vero-E6 cells in a 96-
well-plate. Each dilution of serum was tested in three
wells. The cells were cultured for 1 week to observe
for CPE, and the serum dilution in which 50% of the
cells were protected from infection was calculated.
Pathological examination
Autopsies were performed in the biosafety level 3
(BSL3) animal laboratory at different intervals after
infection. Organs were grossly examined and tis-
sue blocks were taken from the lungs, hilar lymph
nodes, heart, liver, kidneys, intestines, adrenals, thy-
mus, mesentery lymph nodes, and brains. Haema-
toxylin and eosin (H&E) stain, Verhoeff’s stain, peri-
odic acid-Schiff (PAS) stain, Mallory’s connective tis-
sue (MCT) stain, phosphotungstic acid haematoxylin
(PTHA), and Gomori’s stains were used to identify
changes in collagen fibres, elastic and reticulin fibres,
alveolar lining cells, hyaline membranes, and mucus
in the alveolar spaces.
Sections were also stained with monoclonal anti-
bodies (MAbs) for cytokeratin, CD68, and CD35 to
identify the origin of different types of macrophages
in alveoli and in inter-alveolar septa at different times
after virus inoculation. MAbs against CD4 and CD8
were used for T-lymphocyte subset identification.
SARS-CoV antigens were detected in various tis-
sues by immunohistochemical staining. Duplicate sec-
tions of all tissue samples were stained using an
avidin–biotin complex peroxidase technique. De-
waxed sections were pretreated with protease K
(Sigma, St Louis, MO, USA) for 10 min at 37 ◦C,
blocked with 3% hydrogen peroxide and non-immune
goat serum for 30 min, and then incubated with MAbs
against SARS-CoV (1 : 400) overnight at 4 ◦C. These
antibodies were a gift from Dr Yiyou Chen, Starvax,
Inc, Beijing, China and comprised a pool of anti-SARS
spike and anti-SARS nucleocapsid MAbs. The slides
were developed using biotin-labelled goat anti-mouse
antibody according to the manufacturer’s recommen-
dations (Beijing Zhongshan Biotech, China).
Electron microscopy
Samples of lung, spleen, and lymph node were fixed
in 4% formaldehyde and 1% glutaraldehyde, and post-
fixed in 1% osmium tetroxide. Tissue samples were
embedded in epoxy resin Epon812. Thin sections were
doubly stained with uranyl acetate and lead citrate,
and examined under a Tecnai 12 (FEI) transmission
electron microscope.
Results
Clinical signs
Two to three days after SARS-CoV inoculation, all
eight monkeys showed a temporary rise in tempera-
ture that peaked initially at 40 ◦C, but subsequently
subsided to 38 ◦C. There were no remarkable changes
in leukocyte count, and clinical signs and symptoms
including cough, upper respiratory tract catarrh, dys-
pnoea, loss of appetite, vomiting, rash, and diarrhoea
were absent. Moreover, chest radiography was nega-
tive in all of the experimental monkeys in the early
stage after virus inoculation.
Replication and release of virus
SARS coronavirus RNA was detected as a 797 bp
fragment by nested RT-PCR in the pharyngeal swab
and nasal swab samples from the infected macaques
on the first day after infection. Positive results were
found in all eight monkeys (Table 2) from the fifth to
16th day post-infection.
Pharyngeal specimens were cultured with Vero
cells and showed CPE, suggesting the replication
of SARS-CoV. Electron microscopy of Vero cells
with CPE demonstrated typical SARS-CoV parti-
cles in cell culture supernatant using negative stain-
ing. SARS-CoV could also be confirmed by elec-
tron microscopy of the necropsy samples from mon-
keys 1951, 1921, 1924, and 227 (Table 3). Further
Table 2. Experimental results in SARS-CoV-infected Macaca
mulatta
Macaque
identification No
RT-PCR∗
(days)
Virus isolation†
2/5/7 days IgG
2373 2–5 +/−/− −‡
1924 5–7 +/−/− −‡
1951§ 2–10 +/ + /− −‡
883 5–10 −/+/− +
227 5–11 −/−/− +
1921 5–9 −/−/− +
900 1–16 +/−/− +
2372 5–11 −/−/− +
∗ From the fifth day post-infection, nasal and pharyngeal samples from
all monkeys were detected as positive; the longest lasted to day 16.
† Virus isolation is positive if any pharyngeal and nasal swab samples
collected on days 2, 5, and 7 yield positive results.
‡ Macaca mulatta were sacrificed before the tenth day.
§ Inoculated intravenously and via the nasal cavity with lung tissue lysate
from a SARS patient.
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proof came from immunohistochemical detection in
necropsy samples from monkey 1951 at 10 days post-
infection (Figure 1).
Immunological responses
The serum samples obtained from all eight animals
prior to inoculation were negative for anti-SARS
antibodies, but such antibodies were detectable in
five of eight infected monkeys from 11 to 60 days
Table 3. Presence of SARS-CoV in tissues of infected Macaca
mulatta detected by electron microscopy
Macaque identification
No (day sacrificed) Lung
Lymph
node Spleen Liver Kidney
1924∗(7) + + − − −
1951(10) + + + − −
227(20) + − − − −
1921(30) + − − − −
∗ Inoculated intravenously and via the nasal cavity with lung tissue lysate
from a patient infected with SARS-CoV strain PUMC01.
Figure 1. SARS-CoV antigen in lung tissues from infected
Macaca mulatta (No 1951) 10 days after infection. Lung
tissue samples were stained using an avidin–biotin complex
peroxidase technique. Sections were incubated with monoclonal
antibodies against SARS-CoV (1 : 400) and were developed using
biotin-labelled goat anti-mouse antibody. (Immunohistochemical
staining; original magnification ×400)
post-infection. As shown in Table 4, neutralization
assays demonstrated that all tested monkeys were
able to produce neutralizing antibody. The titre of
neutralizing antibody for each monkey was as follows:
No 883, 1 : 4 (15 days post-infection); No 0227, 1 : 2
(20 days post-infection); No 1921, 1 : 4 (30 days post-
infection). Both No 900 and No 2372 showed a titre
of 1 : 64 (60 days post-infection).
Pathological changes
Lung tissue from healthy rhesus monkeys showed nor-
mal alveolar septa, intact reticulin fibres and lining
epithelium, with occasional CD68-positive foam cells
adherent to regenerating epithelial cells (Figure 3). In
striking contrast, lung lesions developed in all eight
SARS-CoV-infected monkeys. Grossly, there was con-
gestion, and palpable nodules, scattered in distribution,
were located particularly in the posterior part of dif-
ferent lobes (Figure 2). Microscopically, lesions were
demonstrated in different organs, particularly in the
lungs where acute haemorrhagic interstitial pneumonia
(Figures 4A, 4B, 5A, 5B, and 7A) or acute interstitial
pneumonia (Figures 4C, 4D, 6C, and 7C) was remark-
able.
Figure 2. Macroscopic appearance of lung tissue of
SARS-CoV-infected monkey 2373 on the fifth day after infection;
local lesions are arrowed
Table 4. Changes of IgG and neutralizing antibody titres in sera from SARS-CoV-infected Macaca mulatta
Macaque identification
No (see Table 1) 0∗ 5 10 15 20 30 40 50 60
2373 − −†
1924 − −†
1951 − − −†
883 − − − 1 : 40‡ (1 : 4)
227 − − 1 : 10 1 : 160 1 : 160 (1 : 2)
1921 − − − − − 1 : 40 (1 : 4)
900 − − − 1 : 80 1 : 80 1 : 320 1 : 160 1 : 160 1 : 160 (1 : 64)
2372 − − 1 : 40 1 : 320 1 : 320 1 : 320 1 : 160 1 : 160 1 : 160 (1 : 64)
∗ Days after infection with SARS-CoV.
† Macaca mulatta were sacrificed on or before the tenth day.
‡ Sera were diluted from 1 : 10. Negative (−) = OD value < 0.16.
Antibody titres were determined on the days when the monkeys were sacrificed and are given in parentheses.
J Pathol 2005; 206: 251–259
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Figure 3
Figure 4
Figure 5
Figure 6
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Figure 3. Lung alveoli of a normal healthy rhesus monkey for comparison. (A) Normal alveolar septa (H&E; original magnification
×200). (A, a) The inter-alveolar septa are narrow; there is no inflammatory cell infiltration or oedema (H&E; original magnification
×200). (A, b) The alveolar sacs are clear; no inflammatory cells are seen in any of the alveoli shown (H&E; original magnification
×200). Panel B, a shows intact reticulin fibres in the alveolar septa; B, b shows small capillaries located in the inter-alveolar septa
(MCT; original magnification ×400). Panel C shows the intact lining epithelium; C, a, b shows positive staining of epithelial cells
with a monoclonal anti-cytokeratin antibody (CK+; original magnification ×1000). Panel D, a, b shows that foam cells staining
positive for CD68 are adherent to regenerating epithelial cells (MAb against human CD68; original magnification ×1000)
Figure 4. Monkey 2373, 5 days after infection. (A, a) Interstitial pneumonia with haemorrhage; (A, b) foam cells (macrophages)
with engulfed red blood cells in the cytoplasm (H&E; original magnification ×200). (B, a) Interstitial pneumonia: macrophage
infiltration is remarkable, with engulfed red blood cells in their cytoplasm; (B, b) lymphocytes and fibrin deposition; (B, c) pleuritis
with oedema, phagocyte and lymphocyte infiltration (H&E; original magnification ×200). (C, a) Haemorrhage; (C, b) macrophages;
(C, c) lymphocytes and macrophages (H&E; original magnification ×200). (D, a) Macrophages packed in the alveolus; (D, b)
lymphocytes; (D, c) foam cells (H&E; original magnification ×400)
Figure 5. Monkey 1924, 7 days after infection. (A, a) Haemorrhage in the inter-alveolar septum; (A, b) engulfed red blood cells in
phagocytes; (A, c) alveoli filled with fibrin, inflammatory cells, and red blood cells; (A, d) lung oedema (HE; original magnification
×400). (B, a) Macrophage with engulfed red blood cell; (B, b) foam cells; (B, c) lymphocytes (H&E; original magnification ×1000).
(C, a) Interstitial pneumonia; (C, b) distended air sacs; (C, c) dilatation of respiratory duct (H&E; original magnification ×200). (D,
a) Macrophages; (D, b) lymphocytes in the inter-alveolar septum (H&E; original magnification ×1000)
Figure 6. Monkey 1951, 10 days after infection. (A, a) Granulation tissue in the damaged bronchiolar wall; (A, b) proliferation of
the lining epithelial cells; (A, c) early regeneration of the damaged epithelium (H&E; original magnification ×200). (B, a) Phagocytes;
(B, b) lymphocytes (H&E; original magnification ×400). (C, a) Lung oedema; (C, b) interstitial pneumonia; (C, c) foam cells (H&E;
original magnification ×400). (D, a) Fragmentation of reticulin fibres in the alveolar wall; (D, b) desquamation of epithelial cells
(Gomori’s stain; ×1000)
The pathological changes found in the lungs and
other organs of monkeys sacrificed at different inter-
vals after viral infection were as follows:
Pathological changes 5 days after virus inoculation (No
2373)
Haemorrhagic interstitial pneumonia (Figures 4A, a, b
and 4B, a–c) and interstitial pneumonia (Figures 4C,
a–c and 4D, a–c) were observed. Inter-alveolar
septa became widened with infiltration of lympho-
cytes, macrophages, foam cells, and macrophages with
engulfed ghost cells (mostly degenerate red blood
cells) in the cytoplasm (Figures 4B, a–c and 4D, a–c).
The alveolar sacs and a few dilated fine bronchioles
were filled with clusters of macrophages.
Pathological changes 7 days after viral inoculation (No
1924)
Haemorrhagic interstitial pneumonia (Figures 5A and
5C) was accompanied by dilatation of the respiratory
ducts (Figure 5C, c) and lung oedema (Figure 5A,
d) in the nodular areas of different lobes. Alveolar
cavities were packed mainly by macrophages and
lymphocytes (Figures 5A, a–c; 5B, a–c; and 5D, a, b).
Phagocytosis of erythrocytes was common (Figure 5B,
a–c).
Pathological changes 10 days after viral inoculation
(No 1951)
Proliferation of epithelial cells or over-excretion of
mucus was remarkable in the small bronchioles.
There was ulceration, granulation tissue formation,
and proliferation of the lining epithelial cells in small
bronchioles (Figure 6A, a–c); infiltrating inflamma-
tory cells were mainly macrophages and lymphocytes
(Figure 6B, a, b). Oedema of the lungs and lesions of
interstitial pneumonia were distinct (Figure 6C, a–c).
Gomori’s silver staining showed destruction and frag-
mentation of the reticulin fibres of the alveolar wall
(Figure 6D, a, b).
Pathological changes in lungs of macaques 15 days (No
883) and 20 days (No 227) after viral inoculation
In monkey 883, interstitial pneumonia was haemor-
rhagic in nature (Figure 7A, a–c), with infiltration of
macrophages and lymphocytes in inter-alveolar septa
(Figures 7A, b, c and 7B, b, c) and necrotic foci in
the liver and left heart similar to the lesions reported
in human autopsy findings [13,14]. Fibrin deposition
was obvious in the alveolar cavities forming part of
the hyaline membrane in alveoli (Figures 7B, a, c and
7C, a–c).
Monkey 227 also had remarkable interstitial pneu-
monia (pneumonitis) in both lungs (Figure 7D). This
was haemorrhagic in some areas, similar to that seen
in case 883 (Figure 7A, b, c). There was accumu-
lation of macrophages and foam cells in the alveoli
(Figure 7D, a).
Pathological changes 30 days after viral inoculation
(No 1921)
Interstitial pneumonia was still detectable in mon-
key 1921 30 days post-infection. The lesions were
scattered in distribution, with infiltration of mononu-
clear inflammatory cells (Figure 8A, a, b) and evi-
dence of chronic pleuritis and emphysema (Figure 8A,
b). Most of the infiltrating cells were CD68-positive
(Figure 8D, a). The spleen was congested with prolif-
eration of red pulp (data not shown). Focal necrosis
J Pathol 2005; 206: 251–259
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Figure 7
Figure 8
Figure 7. Monkey 883, 15 days after infection. (A, a) Interstitial
pneumonia with haemorrhage and fibrin deposition; (A, b)
phagocytes with red blood cell engulfment; (A, c) capillary
congestion (H&E; original magnification ×200). (B, a) Presence
of fibrin filaments between neighbouring alveoli; (B, b) red blood
cells engulfed in phagocytes; (B, c) foam cells (H&E; original
magnification ×400). (C, a) Lung oedema; (C, b) accumulation
of phagocytes in alveoli; (C, c) lymphocytes in the alveolar
septum and the alveoli (H&E; original magnification ×400). (D,
a) Interstitial pneumonia present in monkey 227
Figure 8. Monkey 1921, 30 days after infection. (A, a)
Interstitial pneumonia with mononuclear cell infiltration; (A,
b) localized emphysema (H&E; original magnification ×100). (B,
a) Focal liver necrosis (No 1921); (B, b) degenerate and necrotic
cells; (B, c) lymphocytes; (B, d) liver cells. (C, a) Regenerative
epithelial cells shown to be CK-positive (cytokeratin MAb
stain; original magnification ×1000); (C, b) macrophages. (D, a)
CD68-positive cells (macrophages) adherent to the surface
of regenerative epithelial cells (CD68 MAb stain; original
magnification ×1000); (D, b) regenerative epithelial cells in
small bronchioles
Figure 9. Monkeys 900 and 2372, 60 days after infection. (A,
a) Interstitial pneumonia with mononuclear infiltration (H&E;
original magnification ×50) (No 2372). (A, b) Some alveoli are
distended. (B, a) Mild interstitial pneumonia; (B, b) emphysema
(H&E; original magnification ×100) (No 900). (C, a) Interstitial
pneumonia and infiltration of mononuclear cells; (C, b) foam
cell formation (H&E; original magnification ×200). (D, a) Foam
cells in alveoli; (D, b) phagocytes; (D, c) lymphocytes in septa
(H&E; original magnification ×400)
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was seen in the liver (Figure 8B, a–d). The regenera-
tive epithelial cells of alveoli were cytokeratin-positive
(Figure 8C, a, b). Additionally, CD68-positive cells
(Figure 8D, a, b) were seen to adhere in clumps to the
regenerative epithelial cells of the small bronchioles.
Pathological changes 60 days after viral inoculation
(Nos 2372 and 900)
Foci of interstitial pneumonia were still found in cer-
tain areas of the lungs in both monkeys but were mild
(No 2372, Figure 9A and No 900, Figures 9B–9D).
Some alveoli were markedly distended, accompanied
by localized emphysema (Figures 9A and 9B). Most
of the inter-alveolar septa were well preserved and
there was evidence of infiltration of lymphocytes and
macrophages in inter-alveolar septa (Figure 9A and
monkey 900 in Figures 9C and 9D).
In summary, lesions of acute interstitial pneumonitis
were observed in the monkeys throughout the 60-day
study. There was marked infiltration of lymphocytes
and macrophages in nodular areas in the lungs, partic-
ularly in the early stages, ie 5 and 10 days post- infec-
tion (Figures 4B, a, b and 4D, a–c; and Figures 5B,
a–c and 5D, a, b). Some respiratory ducts were packed
with mucus and cell debris and, in addition, regen-
eration of the lining epithelium was seen simultane-
ously in certain terminal bronchioles (Figures 6A, a–c
and 6B, a, b). Desquamation of alveolar lining cells,
lung oedema, and hyaline membranes in alveoli were
identified in some infected animals (Figures 6C, a–b;
7B, a, b; 7C, a, b; and 7D, a), however, the lung lesions
were less intense compared with the pathological fea-
tures seen in the lungs of patients who died of SARS
[13–15]. The severity of lung infection became mild in
those animals that were sacrificed more than 30 days
after the infection (Figures 8A, 9B, and 9C). In these
animals, there was still infiltration of macrophages and
lymphocytes in the inter-alveolar septa (Figure 8A, a,
b). Fragmentation of reticulin and elastic fibres of the
alveolar wall was common (Figure 6D, a, b). There
was also evidence of fibrous tissue proliferation and
development of emphysema (Figures 8A and 9B).
Discussion
It is important to establish animal models in order to
explore the pathogenesis of SARS and to test new
antiviral therapies and vaccines against SARS. In this
study, we detected sequential pathological changes
in the lungs of macaques from 5–60 days post-
infection with SARS-CoV. The pulmonary lesions
are comparable to, though less intense than, those
of SARS patients. Foci of interstitial pneumonia and
diffuse alveolar damage were observed during the
whole course of the experiment. Repeated haemor-
rhage, oedema, and over-secretion of protein-rich fluid
inevitably resulted in fibrosis of pulmonary tissues.
These pathological changes reflect the changes that
are seen in the early stage of clinical SARS cases
[16–20]. An important observation in these studies is
that there was no SARS-related death in the infected
animals and SARS infections in rhesus macaques were
milder. The differences in clinical signs and symp-
toms, and pathological changes, in the experimentally
infected rhesus macaques compared with human cases
of SARS might be due, in part, to the presence of
co-infections or secondary infections in human cases
[21,22], whereas the monkeys used in this study were
young and healthy. Secondly, treatment given to SARS
patients might have had an impact on the histologi-
cal changes. Thirdly, SARS-CoV might have different
cytopathic effects in humans and rhesus macaques.
SARS-CoV-specific IgG antibody could be detected
in sera of macaques from 11 days post-infection
onwards and the titre increased gradually. Neutralizing
antibody protection assays showed that the infected
animals produced neutralizing antibodies that could
prevent re-infection by SARS-CoV (data not shown).
Our results also demonstrate the potent immuno-
genicity of SARS-CoV, suggesting the possibility
of using the virus to produce inactivated or attenu-
ated vaccines.
A recent report has concluded that the macaque
model is of limited utility in the study of SARS patho-
genesis and the evaluation of therapies [23]. In partic-
ular, the lung lesions in both rhesus and cynomolgus
macaques were infrequent and limited to focal inter-
stitial alveolar inflammation and oedema and lesions
reflecting severe damage to alveolar and bronchial
cell damage were not observed. Our results differ
from those of Rowe et al [23], who showed limited
disease, and those of Fouchier et al [8] and Kuiken
et al [24], who showed in cynomolgus macaques
a more severe pulmonary syndrome that resembled
SARS in several ways. The reasons for these dif-
ferences are not clear, but it should be noted that
rhesus macaques of Chinese origin were used in
our studies and viral RNA could be detected in
all of the infected monkeys, the longest duration
lasting to 16 days. In addition, virus could be iso-
lated from five of eight infected monkeys and neu-
tralizing antibody response persisted in the animals
that were sacrificed at 60 days post-infection. Thus,
based on the results of virus detection, immunologi-
cal response, and pathological changes in the lungs of
infected animals, we conclude that the rhesus macaque
model of SARS is valuable. Furthermore, a long-
term study that simultaneously examines the patho-
logical changes and pro-inflammatory cytokine and
chemokine profiles in the lungs from these animals
might provide insight into the mechanism(s) of SARS-
CoV-mediated lung injury and greatly facilitate the
screening and evaluation of anti-SARS drugs and vac-
cines.
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